Daunorubicin

Description

Daunorubicin is an anticancer agent which is used in the treatment of various types of cancers of the blood. It should be used under the supervision of a qualified physician. Close monitoring of kidney function and blood cell count is necessary while receiving this medication.

Side effects

Major & minor side effects for Daunorubicin

  • Nausea and vomiting
  • Decrease in white blood cells and platelets
  • Infections
  • Diarrhea
  • Mouth ulcers
  • Joint pain
  • Hair loss
  • Shortness of breath

Uses of Daunorubicin

What is it prescribed for?

  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukaemia
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Daunorubicin or any other inactive ingredients present along with it.

Active infections

This medicine is not recommended for use in patients who have an active infection due to the increased risk of worsening of the patient's condition.

Bone marrow suppression

This medicine is not recommended for use in patients with bone marrow suppression due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
General warnings

Effect on heart

Daunorubicin may increase the risk of toxic effects on the heart and could lead to acute left ventricular failure. Patients with a history of heart disease need close monitoring while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Bone marrow suppression

This medicine may cause bone marrow suppression which in turn lowers the white blood cell count (neutrophils) and platelets. Close monitoring of blood cell count is necessary. The baseline of the blood cell count should be obtained before initiation of the treatment. Do not start the treatment if the blood cell count is too low.

Liver and Kidney Impairment

This medicine may increase the risk of toxic effects on the liver and kidney. Evaluation of liver and kidney function should be obtained before initiation of the treatment. Close monitoring of liver and kidney function is recommended during the treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Secondary Malignancies

This medicine is known to increase the risk of secondary cancers including acute leukemia, myeloproliferative syndrome, etc. Close monitoring of signs and symptoms is necessary. The treatment should be discontinued if malignancy develops.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. If you miss any chemotherapy session you should contact your doctor immediately and fix an appointment as recommended.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Live attenuated vaccines and related products

Etanercept

Adalimumab

Clozapine

Diltiazem

Atorvastatin

Disease interactions

Bone marrow suppression

This medicine is not recommended for use in patients with preexisting drug-induced bone marrow suppression which causes anemia and infections due to the increased risk of worsening of the patient's condition. Report any signs or symptoms suggesting infection such as bleeding or symptoms of anemia, fever, sore throat, or local infection during the therapy with this medicine. Close clinical monitoring of hematopoietic function is recommended. An alternative treatment option should be considered based on the clinical condition.

Congestive heart failure

This medicine should be used with caution in patients with heart diseases due to the increased risk of congestive heart failure. Regular monitoring of the cardiac function is recommended while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine. The blood cell counts should be monitored before initiating the treatment. Close monitoring of heart function is necessary while receiving this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works
It works by stopping the growth of cancer cells by inhibiting the DNA synthesis.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antibiotics/antineoplastics

Schedule

Schedule H

[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 6 December 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=227784a8-ce68-4dd4-8ac5-a65265969677

[Internet]. Medicines.org.uk. 2018 [cited 6 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/4004/smpc#

Daunorubicin - DrugBank [Internet]. Drugbank.ca. 2018 [cited 6 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB00694

[Internet]. Ebs.tga.gov.au. 2018 [cited 6 December 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06990-3

How will this medicine affect me?

Consult top doctors online and get an answer now
Consult now
Consult now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 29 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.